Risk factors for the occurrence of bronchiolitis obliterans in children with refractory Mycoplasma pneumoniae pneumonia and the predictive value of the factors
CHENG Gui-Lan, XU Bei-Xue, JIA Lin
Department of Pediatrics, Wanzhou District Maternal and Child Health Hospital, Chongqing 404000, China
Abstract Objective To investigate the risk factors for the occurrence of bronchiolitis obliterans (BO) in children with refractory Mycoplasma pneumoniae pneumonia (RMPP) and their predictive value of the factors. Methods A retrospective analysis was performed for the medical records of 156 children with RMPP who were admitted to the hospital from May 2020 to March 2024. According to the diagnostic criteria for BO, they were divided into a BO group (n=76) and a non-BO group (n=80). A logistic regression analysis was used to investigate risk factors for the occurrence of BO, and the receiver operating characteristic (ROC) curve was used to assess the value of the model established based on the risk factors in predicting BO. Results Compared with the non-BO group, the BO group had a significantly longer duration of fever, a significantly higher leukocyte count, and a significantly lower albumin level (P<0.05). Compared with the non-BO group, the BO group had a significantly lower proportion of children with initiation of macrolide antibiotic therapy within 5 days, initiation of glucocorticoid therapy within 2 weeks, or initiation of bronchoscopic therapy within <2 weeks (P<0.05). The ROC curve analysis showed that the logistic regression model established based on the above six indicators had an area under the curve of 0.901 (95%CI: 0.849-0.953, P<0.001) in predicting the occurrence of BO, with a sensitivity of 0.893 and a specificity of 0.827 at the optimal cut-off value of 0.341. Conclusions The logistic regression model established based on duration of fever, leukocyte count, albumin, initiation of macrolide antibiotic therapy within 5 days, initiation of glucocorticoid therapy within 2 weeks, and initiation of bronchoscopic therapy within 2 weeks has relatively high sensitivity and specificity in predicting the occurrence of BO in children with RMPP.
CHENG Gui-Lan,XU Bei-Xue,JIA Lin. Risk factors for the occurrence of bronchiolitis obliterans in children with refractory Mycoplasma pneumoniae pneumonia and the predictive value of the factors[J]. CJCP, 2024, 26(11): 1182-1186.
CHENG Gui-Lan,XU Bei-Xue,JIA Lin. Risk factors for the occurrence of bronchiolitis obliterans in children with refractory Mycoplasma pneumoniae pneumonia and the predictive value of the factors[J]. CJCP, 2024, 26(11): 1182-1186.
Ha EK, Jin JO, Kim JH, et al. Age-related effects of Mycoplasma pneumoniae infection and subsequent asthma exacerbation in children[J]. Pediatr Pulmonol, 2024, 59(6): 1569-1577. PMID: 38708969. DOI: 10.1002/ppul.26907.
Liu H, Song Q, Yi M, et al. Empowering caregivers of children with bronchiolitis obliterans: the effectiveness of an internet-based follow-up platform[J]. Respir Med, 2024, 229: 107673. PMID: 38763447. DOI: 10.1016/j.rmed.2024.107673.
Zhang H, Yang J, Zhao W, et al. Clinical features and risk factors of plastic bronchitis caused by refractory Mycoplasma pneumoniae pneumonia in children: a practical nomogram prediction model[J]. Eur J Pediatr, 2023, 182(3): 1239-1249. PMID: 36633659. PMCID: PMC10023623. DOI: 10.1007/s00431-022-04761-9.
Li M, Wei X, Zhang SS, et al. Recognition of refractory Mycoplasma pneumoniae pneumonia among Myocoplasma pneumoniae pneumonia in hospitalized children: development and validation of a predictive nomogram model[J]. BMC Pulm Med, 2023, 23(1): 383. PMID: 37817172. PMCID: PMC10566172. DOI: 10.1186/s12890-023-02684-1.
Yuan H, Tian J, Wen L. Serum interleukin-6 and serum ferritin levels are the independent risk factors for pneumonia in elderly patients[J]. Crit Rev Immunol, 2024, 44(5): 113-122. PMID: 38618733. DOI: 10.1615/CritRevImmunol.2024051340.
Yanhong R, Shuai Z, Dan C, et al. Predictive value of lactate dehydrogenase for Mycoplasma pneumoniae necrotizing pneumonia in children based on decision curve analysis and dose: response analysis[J]. Sci Rep, 2024, 14(1): 9803. PMID: 38684810. PMCID: PMC11059402. DOI: 10.1038/s41598-024-60359-1.
Wang L, Liu L, Cheng S, et al. In vitro and in vivo study of andrographolide nanoparticles for the treatment of Mycoplasma pneumoniae pneumonia[J]. Biochem Biophys Res Commun, 2024, 698: 149540. PMID: 38266313. DOI: 10.1016/j.bbrc.2024.149540.
